Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2015

Open Access 01-12-2015 | Research

Hormone-receptor expression and survival patterns in operated cases of female invasive ductal breast carcinoma in Kerala: a retrospective cohort study

Authors: Ajith Vettuparambil, Ravindran Chirukandath, Terence B Culas, Sajna Mathumkunnath Vijayan, Gautham Rajan, Sathidevi Vadakkepura Kuttappan

Published in: World Journal of Surgical Oncology | Issue 1/2015

Login to get access

Abstract

Background

Though breast cancer is the most common cancer among women in Kerala, India, epidemiological data on breast cancer in the state is largely lacking. The objectives of this study were to analyze the survival pattern of female breast carcinoma in this region of the country and to compare the differences in survival with different hormone-receptor expressions.

Methods

One hundred eighty-nine female breast cancer patients who were operated between 1 August 2008 and 3 July 2009 were followed up over telephone to obtain data on five-year survival. Grade, stage of the disease, and hormone-receptor (HR) status were obtained from treatment records. Logistic regression and the Kaplan-Meier survival analysis were used for statistical analysis.

Results

The mean age of the study population was 49.07 (SD, 10.35) years. A majority of the patients had estrogen receptor (ER)+/progesterone receptor (PR) + tumors (n = 103, 54.5%), followed by 72 (38.1%) ER−/PR−, 10 (5.3%) ER−/PR+, and 4 (2.1%) ER+/PR−. Stage of the disease, axillary nodal status, and hormone-receptor status showed statistically significant association with overall survival in breast cancer. Overall survival rate at the end of 5 years was 71.4%. Mortality was found to be highest for the ER − PR − group (47.2%).

Conclusions

Women in Kerala are diagnosed with breast carcinoma at a relatively younger age, yet the overall five-year survival for the disease is low when compared to developed nations. It is imperative that comprehensive breast cancer screening and treatment strategies be developed to enable earlier diagnosis and improve the survival of breast cancer in the state.
Literature
1.
go back to reference Programme NCR. Consolidated Report of the Population based cancer registries 1990–1996. New Delhi: Indian Council of Medical Research; 2001. Programme NCR. Consolidated Report of the Population based cancer registries 1990–1996. New Delhi: Indian Council of Medical Research; 2001.
2.
go back to reference Population based cancer registry, Biennial report, 2000 and 2001, 2002, Department of Epidemiology and Bio-Statistics, Kidwai Memorial Institute of Oncology, Bangalore, India, 2004 and 2005. Population based cancer registry, Biennial report, 2000 and 2001, 2002, Department of Epidemiology and Bio-Statistics, Kidwai Memorial Institute of Oncology, Bangalore, India, 2004 and 2005.
3.
go back to reference National Cancer Registry Programme. Ten year consolidated report of the hospital based cancer registries 1984–1993. In: An assessment of the burden and care of cancer patients. New Delhi: Indian Council of Medical Research; 2001. National Cancer Registry Programme. Ten year consolidated report of the hospital based cancer registries 1984–1993. In: An assessment of the burden and care of cancer patients. New Delhi: Indian Council of Medical Research; 2001.
4.
go back to reference Di CS, Baselga J. Management of breast cancer with targeted agents: importance of heterogenecity. Nat Rev Clin Oncol. 2010;7:139–47.CrossRef Di CS, Baselga J. Management of breast cancer with targeted agents: importance of heterogenecity. Nat Rev Clin Oncol. 2010;7:139–47.CrossRef
5.
go back to reference Fitzgibbons PL, Page DL, Weaver D, Thor AD, Craig Allred D, Clark GM, et al. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966–78.PubMed Fitzgibbons PL, Page DL, Weaver D, Thor AD, Craig Allred D, Clark GM, et al. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966–78.PubMed
6.
go back to reference Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer. Tumori. 2008;94:370–83.PubMed Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer. Tumori. 2008;94:370–83.PubMed
7.
go back to reference Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. ASCO-CAP guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMedCentralPubMed Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. ASCO-CAP guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMedCentralPubMed
8.
go back to reference Blows FM, Driver KE, Schmidt MK, Broeks A, van Leewen FE, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PlosMed. 2010;7(5):e 1000279. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leewen FE, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PlosMed. 2010;7(5):e 1000279.
9.
go back to reference Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of estrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. Clin Pathol. 2000;53:688–96.CrossRef Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of estrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. Clin Pathol. 2000;53:688–96.CrossRef
11.
go back to reference Leong SPL, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik N, et al. Is breast cancer the same disease in Asian and western countries? World J Surg. 2010;34:2308–24.CrossRefPubMedCentralPubMed Leong SPL, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik N, et al. Is breast cancer the same disease in Asian and western countries? World J Surg. 2010;34:2308–24.CrossRefPubMedCentralPubMed
12.
go back to reference Rashmi K, Jaishree S, Satinder SM, Kavita M. Hormone receptor status of breast cancer in the Himalayan region of Northern India. Indian J Surg Oncol. 2011;73(1):9–12.CrossRef Rashmi K, Jaishree S, Satinder SM, Kavita M. Hormone receptor status of breast cancer in the Himalayan region of Northern India. Indian J Surg Oncol. 2011;73(1):9–12.CrossRef
13.
go back to reference Dey S, Boffetta P, Mathews A, Brennan P, Soliman A, Mathew A. Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum South India. Int J Cancer. 2009;125(7):1663–70.CrossRefPubMed Dey S, Boffetta P, Mathews A, Brennan P, Soliman A, Mathew A. Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum South India. Int J Cancer. 2009;125(7):1663–70.CrossRefPubMed
14.
go back to reference Shet T, Agrawal A, Nadkarni M, Palkar M, Havaldar R, Parmar V, et al. Hormone receptors over the last 8 years in a cancer referral centre in India:what was and what is? Indian J Pathol Microbiol. 2009;52(2):171–4.CrossRefPubMed Shet T, Agrawal A, Nadkarni M, Palkar M, Havaldar R, Parmar V, et al. Hormone receptors over the last 8 years in a cancer referral centre in India:what was and what is? Indian J Pathol Microbiol. 2009;52(2):171–4.CrossRefPubMed
15.
go back to reference Manjunath S, Jyothi SP, Rohini K, Marjorie C, Sridhar TS. Estrogen receptor negative breast cancer in India: do we really have higher burden of this subtype? Indian J Surg Oncol. 2011;2(2):122–5.CrossRefPubMedCentralPubMed Manjunath S, Jyothi SP, Rohini K, Marjorie C, Sridhar TS. Estrogen receptor negative breast cancer in India: do we really have higher burden of this subtype? Indian J Surg Oncol. 2011;2(2):122–5.CrossRefPubMedCentralPubMed
16.
go back to reference Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9:R6.CrossRefPubMedCentralPubMed Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9:R6.CrossRefPubMedCentralPubMed
17.
go back to reference Azizun-Nisa Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev. 2008;9:553–6. Azizun-Nisa Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev. 2008;9:553–6.
18.
go back to reference Murthy NS, Agarwal UK, Chaudhry K, Saxena S. A study on time trends in incidence of breast cancer-Indian scenario. Eur J Cancer Care. 2007;16:185–6.CrossRef Murthy NS, Agarwal UK, Chaudhry K, Saxena S. A study on time trends in incidence of breast cancer-Indian scenario. Eur J Cancer Care. 2007;16:185–6.CrossRef
19.
go back to reference Gajalakshmi CK, Shanta V, Swaminathan R, Sankaranarayanan R, Black RJ. A population-based survival study on female breast cancer in Madras India. Br J Cancer. 1997;75:771–5.CrossRefPubMedCentralPubMed Gajalakshmi CK, Shanta V, Swaminathan R, Sankaranarayanan R, Black RJ. A population-based survival study on female breast cancer in Madras India. Br J Cancer. 1997;75:771–5.CrossRefPubMedCentralPubMed
20.
go back to reference Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for Europian adults diagonosed in1995-99: results of the EUROCARE-4 study. Lancet Oncol. 2007;8:773–83.CrossRefPubMed Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for Europian adults diagonosed in1995-99: results of the EUROCARE-4 study. Lancet Oncol. 2007;8:773–83.CrossRefPubMed
21.
go back to reference Tsukuma H, Ajiki W, Ioka A, Oshima A. Research Group of Population-Based Cancer Registries of Japan. Survival of cancer patients diagnosed in 1993–1996: collaborative study of population-based cancer registries in Japan. Jpn J Clin Oncol. 2006;36:602–7.CrossRefPubMed Tsukuma H, Ajiki W, Ioka A, Oshima A. Research Group of Population-Based Cancer Registries of Japan. Survival of cancer patients diagnosed in 1993–1996: collaborative study of population-based cancer registries in Japan. Jpn J Clin Oncol. 2006;36:602–7.CrossRefPubMed
22.
23.
go back to reference Anderson WF, Chu KC, Chatterjee N, Brawely O, Brinton LA. Tumor variants by hormone receptor expression in white patients with node negative breast cancer from the surveillance, epidemiology, and end result data base. J Clin Oncol. 2001;19:18–27.PubMed Anderson WF, Chu KC, Chatterjee N, Brawely O, Brinton LA. Tumor variants by hormone receptor expression in white patients with node negative breast cancer from the surveillance, epidemiology, and end result data base. J Clin Oncol. 2001;19:18–27.PubMed
24.
go back to reference Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, et al. Prognostic value of steroid receptors after long term follow up of 2257 operable breast cancers. Br J Cancer. 1996;73:1545–51.CrossRefPubMedCentralPubMed Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, et al. Prognostic value of steroid receptors after long term follow up of 2257 operable breast cancers. Br J Cancer. 1996;73:1545–51.CrossRefPubMedCentralPubMed
25.
go back to reference Navani S, Bhaduri AS. High incidence of estrogen receptor negative progesterone receptor positive phenotypes in breast cancer: fact or fiction? Indian J Pathol Microbiol. 2005;48(2):199–201.PubMed Navani S, Bhaduri AS. High incidence of estrogen receptor negative progesterone receptor positive phenotypes in breast cancer: fact or fiction? Indian J Pathol Microbiol. 2005;48(2):199–201.PubMed
26.
go back to reference Rhodes A, Jasani B. The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact? J Clin Pathol. 2009;62:95–6.CrossRefPubMed Rhodes A, Jasani B. The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact? J Clin Pathol. 2009;62:95–6.CrossRefPubMed
27.
go back to reference De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, et al. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol. 2008;26:335–6.CrossRefPubMed De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, et al. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol. 2008;26:335–6.CrossRefPubMed
28.
go back to reference Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor alone for adjuvant endocrine therapy in two large breast cancer data bases. J Clin Oncol. 2003;21:1973–9.CrossRefPubMed Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor alone for adjuvant endocrine therapy in two large breast cancer data bases. J Clin Oncol. 2003;21:1973–9.CrossRefPubMed
29.
go back to reference Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;35:1451–67. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;35:1451–67.
30.
go back to reference Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, et al. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol. 2004;22:1769–70.CrossRefPubMed Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, et al. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol. 2004;22:1769–70.CrossRefPubMed
Metadata
Title
Hormone-receptor expression and survival patterns in operated cases of female invasive ductal breast carcinoma in Kerala: a retrospective cohort study
Authors
Ajith Vettuparambil
Ravindran Chirukandath
Terence B Culas
Sajna Mathumkunnath Vijayan
Gautham Rajan
Sathidevi Vadakkepura Kuttappan
Publication date
01-12-2015
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2015
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-015-0582-x

Other articles of this Issue 1/2015

World Journal of Surgical Oncology 1/2015 Go to the issue